Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of semaglutide injection (HD1916) for obesity
CTR20243491Phase 3Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in obesity, Overweight, sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Sep 2024; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20243491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243491.